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Summary Further results are presented from the Swedish two-county breast cancer screening trial. The
reduction in the rate of advanced cancers and of breast cancer mortality in the group allocated to screening
when compared to the control group has accelerated with a further year of follow-up. Mortality due to other
causes and the rate of other cancers remains similar in the two groups. Attention has been focused on the rate
at which cancers start re-emerging among women with negative mammograms. Among women over 50 years
of age at entry to the study, relatively few interval cancers are seen in the first two years after a screening test;
in the third year the rate rises to nearly 50% of the comparable rate in the control group. Among women
aged 40-49 years at entry, by contrast, the rate of interval cancers even in the first post screening year is
nearly 40% of that in the controls and in the second year nearly 70%. In older women in the group allocated
to screening, much of the breast cancer mortality comes from the refusers and little from the interval cancers;
in younger women the picture is reversed. The implications for screening policy, including the interscreening
interval are discussed.
The potential of mass screening to reduce mortality from
breast cancer has been clearly demonstrated by the HIP
study from New York (Shapiro et al., 1982), the Swedish
two-county study (Tabar et al., 1985) and by the studies
from the Netherlands (Colette et al., 1984; Verbeek et al.,
1984). The qeustions that now arise concern the
implementation of breast cancer screening, in particular who
should be screened and how often. The two-county Swedish
study was designed with a longer inter-screening interval
than the HIP or Dutch studies and thus is an invaluable
source of information concerning these questions. This
longer interval gives the opportunity to analyze the incidence
of interval cancers in the second and third years after
screening. It is of special interest to examine how the
incidence of these interval cancers increases as time elapses
since the last screening test (Day et al., 1984; Walter et al.,
1983), especially because interval cancers, i.e. breast
carcinomas diagnosed between screening examinations,
appear to have a similar prognosis to cancers diagnosed- in
an unscreened population (Shapiro et al., 1982; Holmberg et
al., 1986). As the interval cancer incidence approaches to
that of the control population, the effect of screening
disappears. Thus, a necessary condition for effective
screening is that the total incidence of interval cancers is
kept relatively low. Our most recent results have given us the
opportunity to examine the incidence of interval cancers
after the first and second rounds, in each age group. Our
purpose is to study the effect of interval length on the
efficacy of screening.
Subjects and methods
The design of the study has been described in detail
previously (Tab'ar et al., 1985). In brief, a total of 162,981
women aged 40 or more were randomly assigned either to be
offered or not offered regular single-view mammography at
specialised screening centres. The randomisation was
performed on a population-block basis consisting of small
administrative units (parishes, municipalities). Women over
74 years of age at randomisation had a poor record of
attendance and are not considered further in this report.
Women aged 70-74 were invited to the first two screening
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rounds only. Women under 70 at entry have been invited for
screening three or four times. Between the first and second
screenings the average interval was 33 months for women 50
years of age and older and 24 months for women under 50
years of age. Only women aged 40-69 at entry were invited
to the third screening round, for which the average interval
since the second screening round was 24 months in all age
groups. Overall compliance in the three screening rounds was
89.2%, 83.3% and 84.0% respectively. The average length of
follow-up from randomisation to December 31, 1985 is 7.5
years in Kopparberg and 6.5 years in Ostergotland. The
comparability of the study and control groups was assessed
in terms of all causes of death other than from breast cancer
up to December 31, 1985 and in terms of deaths from all
malignant diseases excluding breast cancer. Both measures
are as close as could be expected in the study and control
groups.
Screening of the control population started after the
completion of the third round of screening in those aged 50
years or more at entry and after the fourth screening round
in those under 50 at entry. Breast cancers were treated
according to stage at diagnosis and independently of mode
of detection. In this report, age refers to age at entry to the
study, unless specifically stated otherwise.
Results
The breast cancer rates in the study and control from
randomisation to December 31, 1985 are shown in Table I.
Figure I demonstrates the evolution of the cumulative rates
of advanced cancer in the study and control groups during
the progress of the study, for women aged 40-74 at entry.
The significance of the difference appears in Table II. Table
III gives the mortality from breast cancer in the study and
control groups. The cumulative mortality rates in the two
groups by year since entry into the study are displayed in
Figure 2.
To examine the effect of screening on breast cancer
mortality in greater detail we considered the screening status
of women in the study group who died from breast cancer
(Table IV). Two features of this table are interesting. First,
the proportion of deaths found among women who refused
screening increases rapidly with age, reaching 50% in the 70-
74 age group, and second, the proportion of deaths found
among women with interval carcinomas decreases rapidly
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Table I Frequency of breast cancer cases per 1,000 women aged 40-74 at entry
diagnosed between the date of randomisation and 31 December 1985
The two Axillary nodes
counties Total Stage Stage <20mm positive and/or Ductal
combined invasive I II+ pNX' disseminated in situ
Study
group 15.3 8.9 5.9 0.6 4.1 1.4
Control
group 13.1 4.8 8.0 0.3 5.0 0.4
apNX=Invasive cancer, size <20mm, axillary nodes not examined histologically.
Table II Comparison between the study and control groups of
Stage II or more advanced breast cancers at diagnosisa
Kopparberg county Ostergotland county
Stage II+ Population Stage II+ Population
Study
group 245 39,051 215 39,034
Control
group 174 18,846 279 37,936
X2=25.0 (P<0.001), relative risk=0.72, 95% confidence interval
(0.63, 0.81).
aWomen aged 40-74 at entry.
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Table III Deaths from breast cancer in the study and control
populationsa
Kopparberg county O)stergdtland county
Deaths Populations RR Deaths Population RR
Study group 71 39,051 53 39,034
0.66 0.77
Control group 52 18,846 67 37,936
Combined X2 on I degree of freedom=6.9 (P<0.01). Combined
estimate of relative risk=0.71, 95% confidence interval (0.55, 0.91).
aWomen aged 40-74 at entry.
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Figure 1 Cumulative rates of Stage II and more advanced
breast carcinomas per 104 women in the study and control
groups, the two counties combined. Women aged 40-74 at entry,
+ + Control; * * Study.
with age.- We found that over 50% of deaths from breast
cancer in the 40-49 year age group were from these interval
carcinomas. Among women dying from breast cancer who
attended screening, i.e. diagnosed either at screening or in
the interval between two screenings, the proportion arising
as interval carcinomas decreases significantly with age
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Figure 2 Cumulative mortality rates per 105 women by time
since randomization in the study and control groups, two
counties combined, women aged 40-74 at entry, 0 O
Study; + - - + Control.
(X% =4.8, testing for trend) even though the interval was
shorter in younger women. In each age group roughly one-
third of the breast cancer deaths were observed in the group
diagnosed at screening.
To investigate the ability of mammography to detect early
cancers among women of different ages, the incidence ofMAMMOGRAPHIC SCREENING INTERVAL 549
Table IV Deaths from breast cancer in the study group by screening status at the time
of diagnosis in the two counties combined
Deathsfrom breast cancer among women
Diagnosed
in the period Diagnosed
between in the
randomisation interval Diagnosed
and invitation Diagnosed between among non-
Age group to screening at screening screenings responders Total
40-49 8 13 2 23
50-59 3 13 8 9 33
60-69 1 17 9 14 41
70-74 1 9 3 14 27
All ages 5 47 33 39 124
interval cancers in the years succeeding the first and second
screening rounds was examined. In each year succeeding the
screening test, the number of breast cancer cases that would
have been expected to occur if no screening had been
performed can be calculated from the incidence in the
control group. The difference between this number and the
number actually observed gives an estimate of the number of
cases picked up at previous screening, which would otherwise
have surfaced during the year in question. Table V gives the
number of cases observed and the number of expected if no
screening had been performed, in the first, second and third
years after the first and second screening tests, by decade of
age at randomisation. The ratio of these two numbers gives
the proportional incidence of interval carcinomas. The
results are similar after the first and second screening test
and have been pooled in the final column. This column gives
the estimated proportion of cases detected at the previous
screening, which would have surfaced in each of these yearly
intervals. Figure 3 presents graphically the data of Table V
giving the incidence of interval cancers as a proportion of
the incidence that would be expected in the absence of
screening based on the breast cancer incidence in the control
group. The contrast between the 40-49 year age group and
the older women is striking; in the younger women, the
screening test used in this trial picked up about 60% of the
breast cancers that would otherwise have surfaced in the
succeeding 12 months, and 30% of the breast cancers that
would have surfaced in the second year. The corresponding
figures for the older women are about 85% and 70%, and
even in the third year after screening the test detected 55%
of the cases that would have arisen. Little information is
available for the third year among the younger women, since
screening was scheduled every two years. This difference
between the two age groups is highly significant (2= 14.2;
P<0.001). Of the interval cancers in Table V. 58% were
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Figure 3 Breast cancer incidence among screened women in the
interscreening interval, in age group 40-49 (a) and 50-69 (b) as a
percentage of breast cancer incidence in the control group.
Stage II or worse, a figure close to the percentage of 610% in
the control group, as calculated from Table I. Table VI
shows the proportion of advanced cancers in each ten year
age group among interval cases and those diagnosed at
repeat screening, and for comparison, the controls. It should
be noted that the interval cancer rates may be under-
estimated, as the knowledge that a repeat screening
appointment is imminent may be disincentive to self-
Table V Incidence of interval cancers after the first and second screening tests, relative to the
incidence in the control group, by age, the two counties combined
Interval after
Age screening
group (in months)
40-49
50-59
60-69
0-11
12-23
24-29
0-11
12-23
24-29
0-11
12-23
24-29
Ist interval
No. of cases
2nd interval
No. of cases
Observed Expected Observed Expected
8
8
3
3
12
12
10
15
19
20.5
16.9
5.0
40.5
40.5
26.7
51.0
51.0
39.1
7 19.2
15 17.0
6
10
4
4
11
6
37.7
33.1
8.2
44.4
40.9
16.0
Estimated proportion
(%) ofcancers
detected at
previous screen
(both intervals
combined)
62
32
88
70
54
85
72
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Table VI Proportion of Stage II or more advanced cancers among
interval cancer cases and among those diagnosed at repeat screening,
by age
Proportion ofadvanced carcinomas (%)
Diagnosed at repeat
Age at Interval screenings (2nd and Control
randomisation cancers 3rd combined) group
40-49 58.5 37.9 63.6
50-59 55.3 25.0 58.7
60-69 58.5 16.9 58.4
Total 57.5 23.8 59.2
detection and seeking medical care in the interim. That is,
some women may consciously or unconsciously postpone
diagnosis until the next screening appointment. To
complement Table V and Table VI, Table VII enumerates
the breast cancer deaths among women who have been
screened. An interesting finding is that deaths from breast
cancer among interval cases diagnosed within one year after
screening occurred only in the age group 40-49.
Discussion
Completion of the third round of screening and the average
seven year follow up of the control and study populations
has enabled us to study the effect of interval length on
screening efficacy. There are two major factors which
determine the choice of the interscreening interval. These are
the proportion of cancers emerging as interval cancers and
the prognosis of cancers detected at the repeat screening test.
Particular emphasis is given in this report to the former.
Both in this study and in the HIP study the survival of
interval cancers has been similar to the survival of cancers in
the control group. The reduction of breast cancer mortality
should therefore be greater, the lower the proportion of the
interval cancers. The results of this study provide a
quantitative criterion for comparing different screening
frequencies, Although this criterion is not explicitly in terms
of reduced breast cancer mortality, it is in terms of a
measure directly related to it. This measure, the proportional
incidence of interval cancers, should give an early assessment
of the effectiveness of the screening programme, which
depends on both the frequency of screening and the
sensitivity of the screening test. The proportion of cancers
that appear as interval cancers with different screening
intervals is shown in Table V and Figure 3. Among women
under age 50 the rate of interval cancers returns to the rate
in the control group markedly more rapidly than in older
women; in these younger women much of the effect of
single-view mammography screening has disappeared in the
second year after the screening examination. In the 50-69
age group, the incidence of interval cancers in the third year
after screening is nearly half that in the control group of the
same age. The information about the prognosis of cases
diagnosed at repeat screening is not yet complete from this
study. There are good indications, however, that the breast
cancer mortality in this group will be closely related to the
proportion of advanced carcinomas (see Table VI). In these
particular cases, screening has not been successful in
preventing tumour growth to a potentially fatal stage. The
primary reason is not poor sensitivity in the age groups 50-
69; the low interval cancer rates during the first two years
reflect the high sensitivity of mammography screening in this
age group. Stage II and more advanced breast carcinomas
accounted for 38% of the cancers detected at repeat
screening in age group 40-49; 25% in age group 50-59 and
17% in age group 60-69. Adding these cases to the interval
cancer cases, raises the number of carcinomas unaffected by
screening to an unacceptably high level during the second
year after screening in the age group 40-49 and during the
third year after screening in the 50-69 year age group.
Analysis of the screening history of women dying from
breast cancer reveals an age-related phenomenon (Table
VII). Among women over 70, compliance was low and the
effectiveness of the screening programme was corres-
pondingly reduced, more than half of the deaths from
breast cancer were observed in those who refused screening.
Also, in the 60-69 age group, 34% of the breast cancer
deaths occurred among the refusers. Thus, among women 50
and over, low compliance is a major factor impairing the
effectiveness of mammography screening. If repeat screening
is delayed in more than two years, the increasing rate of
both interval cancers and of advanced cancers detected at
repeat screening is an additional factor jeopardising the
screening effect. By comparison, the sensitivity of screening
women 40-49 with single-view mammography every two
years is low, because this screening test permits the
reappearance of too many interval cancers. These cancers
contributed more than half of the total breast cancer deaths
in this age group. The sensitivity of the screening
examination should be increased; this can be done by using
two-view mammography (Andersson et al., 1981; Bunnell et
al., 1986). In addition to the low sensitivity, the long interval
time (2 years) allowed the occurrence of too many advanced
cancers at repeat screening.
It is clear from these results that for women aged 40 to 49
years single-view mammography every two years is not a
sufficiently effective screening policy. What is needed is a
more sensitive test, more frequently applied; annual two-view
mammography would probaIply provide substantial
improvement. For women over the age of 50, there would
seem to be little scope for much improvement by screening
more frequently than every two years. Less frequent
screening will lead to an appreciable increase in the
frequency of interval cancers and also in the frequency of
Stage II or more advanced tumours. It is tempting to
consider randomised trials of the relative effectiveness of
different screening intervals for women over 50. The logistics
of such trials needs careful evaluation, however. In the
Swedish trial, the results to date on mortality reflect mainly
the effect of the initial round of screening. No effect was
seen for three to four years and significance emerged after
some seven years. To evaluate the effect of screening rounds
after the first will clearly take considerably longer. The
expected difference in breast cancer between, say, yearly
Table VII Screening history of women dying from breast cancer
Interval cancers, months between
Diagnosed diagnosis and last negative screening Diagnosed
atfirst second or
Age group screening 0-11 12-23 24-35 36+ third screening
40-49 5 5 5 3 3
50-59 9 4 3 1 4
60-69 15 3 6 2
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screening and screening every five years is also likely to be
smaller than that seen in this trial. A controlled trial to
evaluate the relative effect of different screening intervals
(e.g. yearly versus every 3 years) would probably require
groups large enough to yield about 350 breast cancer deaths
in the absence of screening. Such a trial would need to be
about three times the size of the Swedish trials of 135,000
women and would need to run for a considerably longer
time. In view of the enormous difficulties to be encountered
in running such a trial, the expected results, which can be
calculated in advance, are not sufficient to justify this
immense effort. A more realistic approach is to analyse the
data already available in the ongoing trials and to monitor
the effectiveness of future breast cancer screening
programmes.
In conclusion we recommend annual two-view mammo-
graphy screening in women aged 40-49, for whom the
maximum interval between two screening examinations
should not exceed 18 months. For women over the age of
50, screening should be performed biennually and the
interval should not exceed two years; little extra benefit
would be gained by screening more frequently than every
two years. A high participation rate is essential to the
success of any screening programme.
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